Risk management in therapeutics: When the patient becomes the last line of defense

Pharmacoepidemiology and Drug Safety

Volumn 11, Issue 8, 2002, Pages 637-639

  Gurwitz, Jerry H ^a   Andrade, Susan E ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CISAPRIDE; GEMFIBROZIL; LIVER ENZYME; METFORMIN; TROGLITAZONE;

DRUG CONTRAINDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; FOLLOW UP; HEALTH HAZARD; HEART ARRHYTHMIA; HUMAN; LACTIC ACIDOSIS; LIVER TOXICITY; PATIENT EDUCATION; PATIENT MONITORING; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; NOTE; RISK MANAGEMENT; THERAPY;

HUMANS; RISK MANAGEMENT; THERAPEUTICS;

EID: 0036902857     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.777     Document Type: Editorial

References (13)

1. MedWatch-Baycol Withdrawal Letter. http: //www.fda.gov/medwatch/safety/2001/baycol2.htm [26 August 2002].
2. Schiff GD, Keehr LM, Sai TT, Bult J. High rates of adverse effects and patient unawareness of withdrawn lipid lowering drug combination in a public hospital clinic. Pharmacoepidemiol Drug Safe 2002; 11: 643-646.
3. MedWatch-Baycol Dear Doc Letter. http://www.fda.gov/medwatch/safety/2001/baycol.htm [4 September 2002].
4. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration Regulatory Action. JAMA 2000; 284: 3036-3039.
5. Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001; 286: 831-833.
6. Horlen C, Malone R, Bryant B, Dennis B, Carey T, Pignone M, Rothman R. Frequency of inappropriate metformin prescriptions. JAMA 2002; 287: 2504-2505.
7. Ross-Degnan D, Soumerai SB, Fortess EE, Gurwitz JH. Examining product risk in context: market withdrawal of zomepirac as a case study. JAMA 1993; 270: 1937-1942.
8. Shojania K, Duncan B, McDonald K, Wachter RM (eds). Making Health Care Safer: a Critical Analysis of Patient Safety Practices. Rockville, MD: Agency for Health Care Research and Quality; 2001. Evidence Report/Technology Assessment No. 43; AHRQ Publication 01-E058.
9. The Leapfrog Group. Patient Safety Survey Results Summary. 17 January 2002. Available at: www.leapfroggroup.org/ Briefing/ResultsSummary 011702.pdf [9 August 2002].
10. Leape LL, Berwick DM, Bates DW. What practices will most improve safety? Evidence-based medicine meets patient safety. JAMA 2002; 288: 501-507.
11. Katz JN, Daltroy LH, Brennan TA, Liang MH. Informed consent and the prescription of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1992; 35: 1257-1263.
12. Kaushal R, Barker KN, Bates D. How can information technology improve patient safety and reduce medication errors in children's health care? Arch Pediatr Adolesc Med 2001; 155: 1002-1007.
13. Murray DM. 'The newest member of my medical team - me.' Boston Globe, 6 August 2002.